Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

831
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
831
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

470
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
470
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

65
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
65
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

418
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
418

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same author

Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials.

American journal of hematology·2026
Same author

An Overview of Dysfibrinogenemia: Pathogenesis, Diagnosis, and Management.

Clinics in laboratory medicine·2026
Same author

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

Blood cancer journal·2026
Same author

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Blood cancer journal·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

18.5K

Venous thromboembolic disease.

Michael B Streiff, Paula L Bockenstedt, Spero R Cataland

    Journal of the National Comprehensive Cancer Network : JNCCN
    |November 15, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Venous thromboembolism (VTE) is a dangerous complication for cancer patients. Identifying high-risk individuals and utilizing thromboprophylaxis can help prevent VTE, guided by clinical practice guidelines.

    More Related Videos

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    17.1K
    Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
    06:44

    Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

    Published on: April 13, 2018

    9.6K

    Related Experiment Videos

    Last Updated: May 6, 2026

    Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
    06:45

    Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

    Published on: February 10, 2023

    18.5K
    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    17.1K
    Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
    06:44

    Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

    Published on: April 13, 2018

    9.6K

    Area of Science:

    • Oncology
    • Hematology
    • Clinical Medicine

    Background:

    • Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients.
    • Cancer patients are at increased risk for VTE, necessitating preventative strategies.

    Purpose of the Study:

    • To highlight the importance of recognizing VTE risk factors in cancer patients.
    • To inform about the utility of risk assessment tools for thromboprophylaxis decisions.
    • To reference the NCCN Guidelines for VTE management in oncology.

    Main Methods:

    • Review of risk factors associated with VTE in cancer.
    • Discussion of risk assessment tools for patient stratification.
    • Reference to established clinical practice guidelines for VTE management.

    Main Results:

    • VTE is a significant cause of morbidity and mortality in patients with cancer.
    • Risk assessment tools aid in identifying patients who may benefit from thromboprophylaxis.
    • Clinical guidelines offer a framework for VTE evaluation and management.

    Conclusions:

    • Early identification of VTE risk factors is crucial for cancer patients.
    • Risk assessment and appropriate thromboprophylaxis are key to preventing VTE.
    • Adherence to NCCN Guidelines ensures comprehensive VTE care in oncology.